STK-001
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 08/30/2019
Pipeline Type
New Drugs in Development
Phase Of Development
Preclinical
Sponsors and Collaborators
Stoke Therapeutics
Mechanism of Action
Mechanism Description
STK-001 is an Antisense oligonucleotide that increases levels of SCN1a mRNA in the cell resulting in increased NaV1.1 protein production thereby restoring the reduced protein to near normal levels.
Populations Tested In
Dravet Syndrome
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD
Location of Clinical Trials
N/A
Clinical Trial link